Navigation Links
UW-Madison spinoff Pedrus finds more to business planning than good science

Pedrus Pharma, a University of Wisconsin-Madison spinout that has sped to the finals in the Governor's Business Plan Contest, may put a stop to the annual flu vaccine hoopla, among other things.

Founders Curtis Brandt and Hansi Dean, both UW-Madison researchers, are developing two drugs based on antiviral peptides discovered in Brandt's lab.......

Full article >>> ration papers were just filed last month."

The company


Pedrus, an acronym of Peptide Drug Strategies, is a drug-discovery company. After taking its first two drugs through trials, it may go on to develop others.

"It turns out that bigger pharmaceutical companies are basically wanting to see a compound get either to the start of phase one or through the phase one clinical ......

Full article >>> st 4-5 years of the company, which we hope will keep the costs down," Brandt said.

The pre-clinical trials, and all of the other development that Pedrus Pharma will be doing with its drug compounds, will need major funding. With eligibility as a company established, Brandt and Dean decided to apply for the Governor's Business Plan Contest because it gave them extra impetus to come up with......

Full article >>>
'"/>

Source:wistechnology.com By Katy Williams 04/18/05


Related biology technology :

1. UW-Madison to receive $125M for bioenergy research center
2. Three finalists named for UW-Madison CIO
3. UW-Madison launches new high-speed research network
4. UW-Madison approves new research institute
5. UW-Madison dean predicts bio-economy will fuel Wisconsin
6. Scott Converse, UW-Madison School of Business, on the innovation mind-set
7. Scott Converse, UW-Madison School of Business, on IT workforce development
8. UW-Madisons Beebe wins scientific award
9. UW-Madison MBA program ranked among best for investment return
10. UW-Madison gets $333,000 for biofuels research
11. UW-Madison enters Kauffman grant competition
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2017)... DIEGO , March 27, 2017  Trovagene, Inc. ... that its Chief Executive Officer, Bill Welch , ... April 4, 2017 at 9:00 AM EDT at the ... .  Bill Welch, and Chief Scientific Officer, Mark ... with investors during the conference.   The presentation ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Human ... report to their offering. ... This report analyzes the Global market for Human Embryonic ... are provided for the period 2014 through 2022. Market data and ... The report profiles 25 companies including many key and niche players ...
(Date:3/23/2017)... ... 2017 , ... AxioMed president, Jake Lubinski, describes the AxioMed ... deformed, which is identical to how the human discs work to distribute force. ... to its natural state along a hysteresis curve, exactly like a healthy human ...
(Date:3/23/2017)... 2017  GlobeImmune, Inc. today announced it has entered ... 12,835,490 shares of its common stock to NantCell, Inc., ... with the sale of its common stock, NantCell has ... to GlobeImmune 200,000 shares, an estimated $2.0 million in ... are pleased to enter into this strategic agreement with ...
Breaking Biology Technology:
(Date:3/27/2017)... , March 27, 2017  Catholic Health ... and Management Systems Society (HIMSS) Analytics for achieving ... Adoption Model sm . In addition, CHS previously ... U.S. hospitals using an electronic medical record (EMR). ... its high level of EMR usage in an ...
(Date:3/24/2017)... , March 24, 2017 The Controller General ... Controller Mr. Abdulla Algeen have received the prestigious international IAIR ... Continue Reading ... ... picture) and Deputy Controller Abdulla Algeen (small picture on the right) have ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 15.1% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
Breaking Biology News(10 mins):